Radiopharm Theranostics (ASX:RAD) Inventory Turnover: 0.00 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Inventory Turnover?

Radiopharm Theranostics ASX:RAD Inventory Turnover is 0.00 as of Jun. 2025. The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Radiopharm Theranostics's Cost of Goods Sold for the six months ended in Jun. 2025 was A$1.98 Mil. Radiopharm Theranostics's Average Total Inventories for the quarter that ended in Jun. 2025 was A$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Radiopharm Theranostics's Days Inventory for the six months ended in Jun. 2025 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Radiopharm Theranostics's Inventory-to-Revenue for the quarter that ended in Jun. 2025 was 0.00.

Radiopharm Theranostics  (ASX:RAD) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Radiopharm Theranostics's Days Inventory for the six months ended in Jun. 2025 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2025 )/Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=0/1.979*365 / 2
=0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Radiopharm Theranostics's Inventory to Revenue for the quarter that ended in Jun. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2025 ) / Revenue (Q: Jun. 2025 )
=0 / 2.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Radiopharm Theranostics Inventory Turnover Related Terms

Radiopharm Theranostics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Inventory Turnover Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Inventory Turnover
0.00 0.00 0.00 0.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Inventory Turnover Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Radiopharm Theranostics Inventory Turnover Calculation

Radiopharm Theranostics's Inventory Turnover for the fiscal year that ended in Jun. 2025 is calculated as

Inventory Turnover (A: Jun. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Jun. 2025 ) / ((Total Inventories (A: Jun. 2024 ) + Total Inventories (A: Jun. 2025 )) / count )
=3.594 / ((0 + 0) / 1 )
=3.594 / 0
=N/A

Radiopharm Theranostics's Inventory Turnover for the quarter that ended in Jun. 2025 is calculated as

Inventory Turnover (Q: Jun. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2025 ) / ((Total Inventories (Q: Dec. 2024 ) + Total Inventories (Q: Jun. 2025 )) / count )
=1.979 / ((0 + 0) / 1 )
=1.979 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Radiopharm Theranostics (ASX:RAD) has a Inventory Turnover of 0.00 as of Jun. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Inventory Turnover too high?
Radiopharm Theranostics' current Inventory Turnover is 0.00.
How does Radiopharm Theranostics' Inventory Turnover compare to VRTX and REGN?
Radiopharm Theranostics' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Inventory Turnover is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.